Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltitrexed + irinotecan every 2 weeks as second-line treatment for metastatic colorectal cancer
ChiCTR-ONC-12002767Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of raltitrexed and irinotecan in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival. Started May 2012; status: completed.
02
Drugs
raltitrexedirinotecan
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR-ONC-12002767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-12002767.